Eur J Radiol:对于前循环血管近端狭窄且病灶区域存在半暗带的患者,何时进行血管内介入治疗是否有区别呢?

2017-06-29 shaosai MedSci原创

如果急性脑卒中患者在扩散加权图与灌注加权图像上存在不匹配区域即半暗带,无论症状发生至治疗间隔多长时间(OTT),缺血性脑卒中和大血管阻塞的患者都能从血管内治疗中获益。而对于血管内治疗时间窗对预后差别的问题一直尚未证实。本研究旨在探究OTT对上述患者临床结局的影响。研究人员并将研究结果发表在Eur J Radiol上。

如果急性脑卒中患者在扩散加权图与灌注加权图像上存在不匹配区域即半暗带,无论症状发生至治疗间隔多长时间(OTT),缺血性脑卒中和大血管阻塞的患者都能从血管内治疗中获益。而对于血管内治疗时间窗对预后差别的问题一直尚未证实。本研究旨在探究OTT对上述患者临床结局的影响。研究人员并将研究结果发表在Eur J Radiol上。

本研究所分析数据来自于一所大学附属三级保健医院。 所有患者均有前循环大血管近端管腔闭塞并有半暗带。 主要结果是评估OTT对血管介入术后3个月改良Rankin 量表评分的影响,并二分为0-2分为治疗效果良好(0-2),治疗效果较差(3-6)。 次要结果是OTTmRS评分变化的影响。 将在早期时间窗(<340min)和晚期时间窗(≥340min)内治疗的患者进行比较。

本研究共纳入139例缺血性脑卒中的患者。 与在晚期时间窗治疗的患者相比,早期时间窗治疗患者的有利结局明显较高(31例(49%),20例(27%),p = 0.005)。 经调整参数后,多元Logistic回归显示在晚期时间窗内治疗是有利结局的独立阴性预测因子(OR0.39IC[0.18-0.84] p = 0.016)。 同时,在晚期时间窗内治疗的患者mRS评分更高(p = 0.015)。对于灵敏度,将OTT视为连续变量时,OTT仍然是独立的预测因子。 根据大型试验(DEFUSE 2DEFUSE 3SWIFT-PRIMEEXTEND-IA)对半暗带的定义,该上述结果是在具有半暗带的患者中得到的。

研究表明,对于病变区域DWI-PWI不匹配的缺血性脑卒中患者,临床结果是随时间而变化的。

原始出处:

Mundiyanapurath S Diatschuk S Loebel S et al. Outcome of patients with proximal vessel occlusion of the anterior circulation and DWI-PWI mismatch is time-dependent. Eur J Radiol. 2017. DOI 10.1016/j.ejrad.2017.03.016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1967086, encodeId=0163196e086b3, content=<a href='/topic/show?id=72e089518b5' target=_blank style='color:#2F92EE;'>#血管内介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89518, encryptionId=72e089518b5, topicName=血管内介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Tue Jan 30 00:27:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974073, encodeId=493119e4073cf, content=<a href='/topic/show?id=277c8952065' target=_blank style='color:#2F92EE;'>#血管内介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89520, encryptionId=277c8952065, topicName=血管内介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Sun Oct 01 05:27:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579494, encodeId=d7a515e949447, content=<a href='/topic/show?id=3afd942e905' target=_blank style='color:#2F92EE;'>#近端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94279, encryptionId=3afd942e905, topicName=近端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da2116536440, createdName=hittouch, createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581845, encodeId=1f42158184550, content=<a href='/topic/show?id=9aeb35818a2' target=_blank style='color:#2F92EE;'>#半暗带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35818, encryptionId=9aeb35818a2, topicName=半暗带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=165816877056, createdName=12498cbcm05(暂无昵称), createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217375, encodeId=c27721e375a9, content=好好学习,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Sat Jul 01 11:05:30 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1967086, encodeId=0163196e086b3, content=<a href='/topic/show?id=72e089518b5' target=_blank style='color:#2F92EE;'>#血管内介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89518, encryptionId=72e089518b5, topicName=血管内介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Tue Jan 30 00:27:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974073, encodeId=493119e4073cf, content=<a href='/topic/show?id=277c8952065' target=_blank style='color:#2F92EE;'>#血管内介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89520, encryptionId=277c8952065, topicName=血管内介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Sun Oct 01 05:27:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579494, encodeId=d7a515e949447, content=<a href='/topic/show?id=3afd942e905' target=_blank style='color:#2F92EE;'>#近端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94279, encryptionId=3afd942e905, topicName=近端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da2116536440, createdName=hittouch, createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581845, encodeId=1f42158184550, content=<a href='/topic/show?id=9aeb35818a2' target=_blank style='color:#2F92EE;'>#半暗带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35818, encryptionId=9aeb35818a2, topicName=半暗带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=165816877056, createdName=12498cbcm05(暂无昵称), createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217375, encodeId=c27721e375a9, content=好好学习,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Sat Jul 01 11:05:30 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1967086, encodeId=0163196e086b3, content=<a href='/topic/show?id=72e089518b5' target=_blank style='color:#2F92EE;'>#血管内介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89518, encryptionId=72e089518b5, topicName=血管内介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Tue Jan 30 00:27:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974073, encodeId=493119e4073cf, content=<a href='/topic/show?id=277c8952065' target=_blank style='color:#2F92EE;'>#血管内介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89520, encryptionId=277c8952065, topicName=血管内介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Sun Oct 01 05:27:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579494, encodeId=d7a515e949447, content=<a href='/topic/show?id=3afd942e905' target=_blank style='color:#2F92EE;'>#近端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94279, encryptionId=3afd942e905, topicName=近端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da2116536440, createdName=hittouch, createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581845, encodeId=1f42158184550, content=<a href='/topic/show?id=9aeb35818a2' target=_blank style='color:#2F92EE;'>#半暗带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35818, encryptionId=9aeb35818a2, topicName=半暗带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=165816877056, createdName=12498cbcm05(暂无昵称), createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217375, encodeId=c27721e375a9, content=好好学习,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Sat Jul 01 11:05:30 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
    2017-07-01 hittouch
  4. [GetPortalCommentsPageByObjectIdResponse(id=1967086, encodeId=0163196e086b3, content=<a href='/topic/show?id=72e089518b5' target=_blank style='color:#2F92EE;'>#血管内介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89518, encryptionId=72e089518b5, topicName=血管内介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Tue Jan 30 00:27:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974073, encodeId=493119e4073cf, content=<a href='/topic/show?id=277c8952065' target=_blank style='color:#2F92EE;'>#血管内介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89520, encryptionId=277c8952065, topicName=血管内介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Sun Oct 01 05:27:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579494, encodeId=d7a515e949447, content=<a href='/topic/show?id=3afd942e905' target=_blank style='color:#2F92EE;'>#近端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94279, encryptionId=3afd942e905, topicName=近端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da2116536440, createdName=hittouch, createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581845, encodeId=1f42158184550, content=<a href='/topic/show?id=9aeb35818a2' target=_blank style='color:#2F92EE;'>#半暗带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35818, encryptionId=9aeb35818a2, topicName=半暗带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=165816877056, createdName=12498cbcm05(暂无昵称), createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217375, encodeId=c27721e375a9, content=好好学习,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Sat Jul 01 11:05:30 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1967086, encodeId=0163196e086b3, content=<a href='/topic/show?id=72e089518b5' target=_blank style='color:#2F92EE;'>#血管内介入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89518, encryptionId=72e089518b5, topicName=血管内介入)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Tue Jan 30 00:27:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974073, encodeId=493119e4073cf, content=<a href='/topic/show?id=277c8952065' target=_blank style='color:#2F92EE;'>#血管内介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89520, encryptionId=277c8952065, topicName=血管内介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Sun Oct 01 05:27:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579494, encodeId=d7a515e949447, content=<a href='/topic/show?id=3afd942e905' target=_blank style='color:#2F92EE;'>#近端#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94279, encryptionId=3afd942e905, topicName=近端)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da2116536440, createdName=hittouch, createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581845, encodeId=1f42158184550, content=<a href='/topic/show?id=9aeb35818a2' target=_blank style='color:#2F92EE;'>#半暗带#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35818, encryptionId=9aeb35818a2, topicName=半暗带)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=165816877056, createdName=12498cbcm05(暂无昵称), createdTime=Sat Jul 01 14:27:00 CST 2017, time=2017-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=217375, encodeId=c27721e375a9, content=好好学习,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLANEL7Sww3HicKsN9aribicAmGGWXOIMEiaZ1iadgZg9RibjqSwIKUS8gSPib2NwTVg2zVvVJhdP3BkuDIl/0, createdBy=944d1605392, createdName=shaosai, createdTime=Sat Jul 01 11:05:30 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
    2017-07-01 shaosai

    好好学习,涨知识

    0

相关资讯

NEJM:对糖尿病患者行冠脉洗脱支架,依维莫司优于紫杉醇

药物洗脱支架的选择目前仍存在争议。先前有研究比较了紫杉醇洗脱支架和雷帕霉素(或与其类似药物如依维莫司、唑他莫司)洗脱支架,但得出了矛盾的结果。

JAMA :血管内超声指导下行药物涂层支架植入会更安全

对复杂冠状动脉病变进行冠状动脉介入时,使用血管内超声显像 (IVUS) 可以得到更好的临床结局。不过有数据表明,当使用药物洗脱支架治疗时,IVUS的临床应用就会受到限制。研究者进行了一项研究,探究长冠状动脉病变(植入支架长度 ≥28 mm)患者进行药物洗脱支架植入时,通过IVUS能否更优于血管造影术。该随机多中心研究纳入了1400名患者,使用依维莫司涂层支架植入时,随机使用IVUS(n=700)或

Heart:冠状动脉慢性完全闭塞病变:介入治疗 vs 药物治疗

目前关于冠状动脉慢性完全闭塞病变(CTO)的治疗(选择性药物治疗 vs 经皮冠状动脉介入治疗 (PCI))的结局相关数据还很少。因此研究者对CTO患者进行了一项连续队列研究,比较该患者选择药物治疗和PCI治疗的长期临床结局。该研究纳入了2002-2007年间血管造影诊断为CTO的1957名患者。其中 405 (20.7%)名患者选择PCI, 667 (34.1%)名患者选择药物治疗,885 (45

ESC 2015:ACS介入治疗的股动脉和桡动脉之争结束

Normal 0 10 pt 0 2 false false false EN-US ZH-CN X-NONE

学术导读:我国介入呼吸病学发展现状及展望

近些年,我国介入呼吸病学得到长足发展,特别是2011年中华医学会呼吸病学分会介入呼吸病学组成立后,全国各地介入诊治中心、介入培训基地陆续成立,呼吸介入领域开始迅猛发展。本文简要介绍了我国介入呼吸病学的发展历程以及取得的成绩,同时还指出存在规范化不足、医师培训体系有待完善、临床研究欠缺等短板,希望通过更高层次的“规范、普及、提高”,加强技术规范和评价体系建设,进一步推动我国介入呼吸病学事业的发展。

OCC 2017:韩雅玲院士——冠心病介入治疗新近进展

今天召开第11届东方心脏病学会议(OCC)上,来自沈阳军区总医院全军心血管病研究所心内科的韩雅玲院士从三个方面:心肌血运重建策略的新证据、PCI相关的药物治疗进展、新型支架研究进展,回顾了2016~2017年以来冠心病介入治疗领域的新进展。 一、 心肌血运重建策略的新证据 1.EXCEL研究选取了2905名上低中危(SYNTAX得分≤32)无保护左主干患者,最终纳入1905名患者比